SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle's stock is trending due to a significant after-hours drop following its earnings report, despite an EPS beat, as revenue concerns and increased capital expenditures spooked investors. The community is actively discussing the implications of the results on Oracle's debt and future growth, particularly in the AI space, with some questioning the company's long-term viability while others see a buying opportunity amidst the volatility.

Beasley Broadcast Group, Inc. is multi-platform media company, which engages in the operation of radio stations in the United States. The firm offers marketing solutions across event platforms. It operates through the following business segments: Audio, Digital, and Other. The company was founded by George G. Beasley in 1961 and is headquartered in Naples, FL.

Beasley Broadcast Group Inc - Ordinary Shares - Class A

BBGI is trending due to a massive intraday surge, sparking discussions about potential short squeezes and after-hours momentum. The stock's volatile price action and frequent trading halts have captivated community attention, with some comparing it to previous high-flying, low-float stocks. Traders are actively debating whether to hold overnight for further gains or take profits amidst the volatility.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending amidst a potential bidding war for Warner Bros. Discovery (WBD), with community discussions focused on whether Netflix will increase its offer or walk away; a Paramount bid could allow Netflix to collect a termination fee. Some investors worry about the debt Netflix would incur if it wins the bidding war, while others speculate about political motivations affecting the deal.

Adobe, Inc. is a global technology company, which engages in the provision of digital marketing and media solutions. It operates through the following segments: Digital Media, Digital Experience, and Publishing and Advertising. The Digital Media segment offers products and services that enable individuals, teams, businesses, and enterprises to create, publish, and promote content anywhere and accelerate productivity by transforming view, share, engage with and collaborate on documents and creative content. The Digital Experience segment focuses on integrated platform and set of products, services, and solutions that enable businesses to create, manage, execute, measure, monetize, and optimize customer experiences that span from analytics to commerce. The Publishing and Advertising segment includes legacy products and services that address diverse market opportunities, including eLearning solutions, technical document publishing, web conferencing, document and forms platform, web app development, high-end printing, and Adobe Advertising offerings. The company was founded by Charles M. Geschke and John E. Warnock in December 1982 and is headquartered in San Jose, CA.

Adobe Inc

Adobe is trending as investors discuss the company's upcoming earnings report and its potential in the AI landscape. While some express concerns about competition from AI and other platforms, others highlight Adobe's established position and potential for growth, emphasizing its AI integration and buyback program.

Mawson Infrastructure Group, Inc. engages in the provision of digital asset infrastructure services. The company was founded on February 10, 2012 and is headquartered in Midland, PA.

Mawson Infrastructure Group Inc

Mawson Infrastructure Group ($MIGI) is trending due to increasing interest in its infrastructure growth and expansion into AI and GPU services, differentiating it from typical miners. Community members are actively discussing the stock's low float and potential for a significant short squeeze, with some eyeing price targets between $12 and $40 if catalysts emerge. Traders are also anticipating potential news from an upcoming conference presentation.

Gemini Space Station, Inc. is a holding company, which offers a mobile and web based crypto asset exchange platform, proprietary wallet infrastructure and custody solutions, over-the-counter trading solutions tailored to institutions and professionals, a digital art auction platform, a proprietary United States dollar backed stablecoin, and a credit card product that offers crypto asset rewards on customer purchases. The company was founded by Tyler Winklevoss and Cameron Winklevoss in 2014 and is headquartered in New York, NY.

Gemini Space Station Inc. - Ordinary Shares- Class A

Gemini Space Station

Gemini Space Station ($GEMI) is trending following the approval of a Designated Contract Market (DCM) license from the CFTC, allowing it to launch prediction markets. The community is discussing the potential for a short squeeze and comparing Gemini's prospects to other players in the prediction market space. Some investors see this as a bullish catalyst, while others express skepticism given GEMI's performance since its IPO.

Enveric Biosciences, Inc. is a biotechnology company which engages in the development of neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company was founded on February 28, 1994 and is headquartered in Cambridge, MA.

Enveric Biosciences Inc

Enveric Biosciences is trending due to a U.S. patent allowance for its EVM301 series, sparking discussions of a potential short squeeze given the stock's low float; community members are weighing the IP news against the company's history of dilution. Some traders are also speculating about a potential settlement with AbbVie, which could boost the stock.

Synopsys, Inc. engages in the provision of electronic design automation (EDA) software that engineers use to design and test integrated circuits (ICs). It also offers semiconductor intellectual property (IP) products. It operates through the following segments: Design Automation, Design IP, and Software Integrity. The Design Automation segment includes silicon design, verification products and services, system integration products and services, digital, custom, and FPGA IC design software, verification software and hardware products, and manufacturing software products. The Software Integrity segment includes a solution for building security and compliance testing into the customers' software development lifecycle and supply chain. The company was founded by Aart J. de Geus, Bill Krieger, Dave Gregory, and Rick Rudell in December 1986 and is headquartered in Sunnyvale, CA.

Synopsys, Inc.

Synopsys Inc

Synopsys ($SNPS) is trending after a significant investment from Nvidia, fueling optimism around AI-driven chip design and engineering; the community is closely watching whether this partnership marks a turning point for the stock, which experienced a notable drop after its recent earnings report, and many are hoping this investment will lead to new all-time highs. Some investors are also closely monitoring the impact of potential restrictions on semiconductor software exports to China, a key market for Synopsys.

GlucoTrack, Inc. designs, develops, and commercializes non-invasive glucose monitoring devices for use by persons suffering from diabetes. The company offers the GlucoTrack model DF-F glucose monitoring device, which utilizes a patented combination of ultrasound, electromagnetic and thermal technologies to obtain glucose measurements in less than one minute via a small sensor that is clipped onto one's earlobe and connected to a small, handheld control and display unit, all without drawing blood or interstitial fluid. It was designed to help people with diabetes and pre-diabetics obtain glucose level readings without the pain. The company was founded by Avner Gal and David Malka in September 2001 and is headquartered in Rutherford, NJ.

GlucoTrack Inc

GCTK is trending due to a recent $20 million investment agreement, sparking significant community discussion about its potential impact and speculation of a short squeeze given the stock's low float. Bullish sentiment is fueled by the anticipation of upcoming news and technical indicators suggesting further upward movement, though some traders caution about potential dilution. The community is actively debating price targets and whether the stock can sustain its gains.

Planet Labs PBC provides daily data and insights about earth. It offers a web-geo platform with satellite data available and foundational analytics to derive insights to make decisions. The company is founded by William S. Marshall and Robert H. Schingler in 2010 and is headquartered in San Francisco, CA.

Planet Labs PBC - Ordinary Shares - Class A

Planet Labs PBC

Planet Labs is trending due to strong earnings, a recent acquisition, and increased price targets from analysts, driving positive after-hours movement. The community is excited about the company's growth, particularly its partnerships and expanding presence in the defense and intelligence sectors. Discussions revolve around the potential for all-time highs and a continued bullish outlook for this space-based data provider.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Chimerix Inc. (CMRX) more than tripled on Tuesday afternoon, reaching levels unseen in over two years, becoming one of the top 25 most active tickers on Stocktwits.&nbsp;The microcap biopharmaceutical company announced plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Dordaviprone under the Accelerated Approval pathway by the end of the year.&nbsp;Dordaviprone is being developed as a treatment for certain patients with diffuse glioma, a rare and aggressive type of brain cancer.Chimerix noted that Dordaviprone has received Rare Pediatric Disease Designation for H3 K27M-mutant glioma and said it intends to apply for a Rare Pediatric Disease Priority Review Voucher along with its NDA submission.CEO Mike Andriole emphasized the potential impact of the drug, stating: “If approved, dordaviprone will fundamentally change the treatment landscape for patients suffering from this lethal form of brain cancer who have extremely limited treatment options.”&nbsp;“We have worked collaboratively with the U.S. FDA, disease experts and patient advocates throughout the year to potentially accelerate access to dordaviprone for this patient community,” he added.The company also announced preparations for a potential U.S. launch by the third quarter of 2025, contingent on application acceptance and Priority Review.Following the news, JonesResearch raised its price target on Chimerix to $7 from $5 while maintaining a ‘Buy’ rating.&nbsp;Analysts highlighted the company’s strategic focus on the U.S. NDA submission while halting Australian approval efforts.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/CMRX_sentiment_and_message_volume_Dec_10_premarket_4d3fa2af57.png" alt="CMRX sentiment and message volume Dec 10 premarket.png" width="1318" height="324"><figcaption>CMRX sentiment and message volume Dec 10 as of 1:15 pm ET | source: Stocktwits</figcaption></figure>Retail sentiment for CMRX turned 'extremely bullish', with users on Stocktwits highlighting the stock’s potential for further gains.<stembedurl>https://stocktwits.com/jengtap/message/595886939</stembedurl><stembedurl>https://stocktwits.com/investvibes/message/595887869</stembedurl>Chimerix shares, whose message volume has spiked over 2,540% in the past week, have surged nearly 200% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a medicine pill is seen in a hand dressed in a medical glove with the U.S. FDA logo in the background. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images) 

Chimerix Stock Draws Heavy Retail Chatter After Landing Price-Target Hike On FDA Submission Plan For Cancer Drug 

Following the news, JonesResearch raised its price target on Chimerix to $7 from $5 while maintaining a ‘Buy’ rating.

Equity

Shares of GeoVax Labs Inc. (<a class="mention" data-mention="$GOVX" data-symbol-id="GOVX" href="https://stocktwits.com/symbol/GOVX" target="_blank">$GOVX</a>), SIGA Technologies Inc. (<a class="mention" data-mention="$SIGA" data-symbol-id="SIGA" href="https://stocktwits.com/symbol/SIGA" target="_blank">$SIGA</a>), and Emergent Biosolutions Inc. (<a class="mention" data-mention="$EBS" data-symbol-id="EBS" href="https://stocktwits.com/symbol/EBS" target="_blank">$EBS</a>) gained in mid-day trading on Friday after the World Health Organisation (WHO) reaffirmed that the ongoing upsurge of mpox remains a public health emergency of international concern (PHEIC).Mpox, formerly called monkeypox, is a disease similar to smallpox caused by a virus.&nbsp;“The decision was based on the rising number and continuing geographic spread of cases, operational challenges in the field, and the need to mount and sustain a cohesive response across countries and partners,” the apex health agency said in a&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/WHO/status/1860015125463175343">post</a> on X (formerly Twitter).&nbsp;<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_11_22_132250_27d9a22ffc.png" alt="Screenshot 2024-11-22 132250.png">The WHO first declared mpox a PHEIC in August earlier this year because a new strain of the virus, Clade Ib, had spread to countries that had not previously reported any incidences of the disease, like Thailand and Sweden.&nbsp;Shares of GeoVax, currently working on a vaccine for mpox and smallpox, were up nearly 10% in mid-day trading on Friday. The stock has lost 47% of its value this year so far.&nbsp;<stembedurl>https://stocktwits.com/gabbs/message/593724551</stembedurl>Meanwhile, shares of SIGA Technologies Inc. (<a class="mention" data-mention="$SIGA" data-symbol-id="SIGA" href="https://stocktwits.com/symbol/SIGA" target="_blank">$SIGA</a>), developing an investigational drug for treating mpox called tecovirimat (TPOXX),&nbsp; jumped 2.5% after the news.&nbsp;<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_11_22_134247_8c8f14c041.png" alt="Screenshot 2024-11-22 134247.png">Retail sentiment around the stock improved to ‘bullish’ (60/100) from ‘neutral’ a day ago.&nbsp;SIGA Technologies’ shares have gained 11% this year so far.There was less movement around Emergent Biosolutions Inc. (<a class="mention" data-mention="$EBS" data-symbol-id="EBS" href="https://stocktwits.com/symbol/EBS" target="_blank">$EBS</a>), also working on a vaccine for mpox, which saw a marginal uptick of 0.6% in mid-day trading on Friday.&nbsp;<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_11_22_134547_d67811671e.png" alt="Screenshot 2024-11-22 134547.png">Retail sentiment around the stock remained in the ‘neutral’ zone with no significant change in chatter.&nbsp;Emergent Biosolutions’ vaccine, approved for smallpox, has also been used as a mpox shot, but the U.S. Food and Drug Administration is yet to approve its application for use against the virus.<stembedurl>https://stocktwits.com/WinstonSmith33/message/593679534</stembedurl>In 2022, the company acquired the rights to a smallpox treatment called Tembexa, which was developed by Chimerix Inc. ($CMRX), for up to $337.5 million plus royalties.Chimerix was up around 0.6% as well during mid-day trading.&nbsp;For updates and corrections email newsroom[at]stocktwits[dot]com.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/agrify-stock-doubles-to-hit-over-1-year-high-after-25-9-m-placement-but-retail-wary-of-short-covering-rally/cJIdTKHRg3">Agrify Stock Doubles To Hit Over 1-Year High After $25.9M Placement, But Retail Wary Of Short-Covering Rally</a>

Mpox, formerly called monkeypox, is a disease similar to smallpox caused by a virus. | Source: Pexels

GeoVax, SIGA Jump After WHO Extends Mpox Public Emergency Status: Here’s What Retail Thinks

Emergent Biosolutions and Chimerix also saw marginal gains after the announcement. 

<h1>These Three Stocks are Experiencing an Outbreak– Or a Breakout Depending How you Look at it</h1><h3>Monkeypox Outbreak Fuels Surge in Related Biopharma Stocks</h3>The recent resurgence of monkeypox has sparked widespread concern and reignited the market's interest in companies working to combat viral diseases. As the outbreak spreads, parallels to the COVID-19 pandemic are being drawn in both the media and financial markets. During the COVID-19 crisis, pharmaceutical companies that developed vaccines, treatments, and diagnostics experienced unprecedented growth, with investors flocking to these stocks in search of gains. Now, as the world faces another potential health emergency, a new set of companies is stepping into the spotlight.The global health community and investors alike are keeping a close eye on monkeypox, a disease caused by the monkeypox virus, which shares similarities with smallpox. While the outbreaks have been sporadic and relatively contained in the past, recent concerns have shifted focus toward vaccine and treatment development. The monkeypox market, although smaller in scope than COVID-19, holds significant potential. The World Health Organization and public health bodies are calling for increased awareness, testing, and vaccination. As a result, companies developing monkeypox-related therapies and vaccines are seeing their stock prices soar.Three such companies—GeoVax Labs, Tonix Pharmaceuticals, and Chimerix—are garnering substantial interest. All three have ties to the smallpox market, which, in turn, gives them relevance in the monkeypox conversation. Below is a review of these companies, their roles in combating the outbreak, and their stock performance over the short, medium, and long term.<a href="https://wealthyvc.com/featured/tiny-healthcare-stock-with-35-million-market-cap-becomes-major-player-overnight-in-rapidly-growing-1-billion-market/">This Tiny Healthcare Stock With $35M Market Cap Becomes Major Player Overnight in Rapidly Growing $1 Billion Blood Clot Market</a><a href="https://stocktwits.com/symbol/GOVX">GeoVax Labs (NASDAQ: GOVX)</a>GeoVax Labs has emerged as one of the frontrunners in the monkeypox vaccine race. Based in Georgia, this clinical-stage biotechnology company specializes in vaccines that leverage its proprietary Modified Vaccinia Ankara Virus-Like Particle (MVA-VLP) platform. The company has been developing vaccines for various infectious diseases, including smallpox, Ebola, and Lassa fever. However, with the recent monkeypox outbreak, GeoVax's focus on viral hemorrhagic fevers and poxvirus diseases has become particularly relevant.GeoVax's stock soared as concerns around monkeypox escalated, with investors seeing potential in its MVA-based vaccine technology. Its smallpox vaccine is designed to offer cross-protection against monkeypox due to the close relation between the two viruses. This has made GeoVax a significant player in the biopharma space, as public health agencies explore all options for controlling the spread of the virus.<ul><li>1-Day Return: +33%</li><li>1-Month Return: +234%</li><li>1-Year Return: +21%</li></ul>GeoVax shares have experienced strong upward momentum over the past month, driven by mounting concerns over monkeypox. Over the past year, the stock has gained substantial value as the company has positioned itself as a leader in the viral vaccine space.<a href="https://stocktwits.com/symbol/TNXP">Tonix Pharmaceuticals (NASDAQ: TNXP)</a><a href="https://stocktwits.com/symbol/TNXP"><img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_08_19_at_9_53_43_PM_2ed6d91698.png" alt="Screenshot 2024-08-19 at 9.53.43 PM.png"></a>Tonix Pharmaceuticals, another biotech firm in the spotlight, is developing live virus vaccines that may offer protection against monkeypox and other orthopoxvirus diseases. Based in New Jersey, Tonix has focused on immunology, chronic diseases, and rare infectious diseases. One of its notable projects is its live virus vaccine candidate, TNX-801, designed to protect against both smallpox and monkeypox.A recent Benzinga article highlighted the company’s preclinical results, which demonstrated long-term immunity and protection against these viruses. Tonix’s TNX-801 is based on a horsepox viral platform, which is closely related to smallpox and monkeypox. The company is working on creating a robust, durable immune response that can withstand mutations and future outbreaks. What makes Tonix attractive is the potential for TNX-801 to be used as a preventive measure in populations at high risk of contracting monkeypox.<ul><li>1-Day Return: +40%</li><li>1-Month Return: +12%</li><li>1-Year Return: -98%</li></ul>Tonix Pharmaceuticals has seen a notable rise in its stock price over the past month, as interest in its vaccine candidate has intensified. However, the stock’s performance over the past year reflects the inherent volatility in biotech investing, with a significant drop amid broader market conditions and uncertainty in the clinical trial space.<a href="https://stocktwits.com/symbol/CMRX">Chimerix, Inc. (NASDAQ: CMRX)</a><a href="https://stocktwits.com/symbol/CMRX"><img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_08_19_at_9_54_50_PM_c72f46e0e8.png" alt="Screenshot 2024-08-19 at 9.54.50 PM.png"></a>Chimerix, Inc., a biotechnology company based in North Carolina, is another name linked to the monkeypox outbreak. While the company gained attention for its smallpox drug, Tembexa, the renewed interest in orthopoxviruses like monkeypox has brought Chimerix back into the conversation. Tembexa (brincidofovir) is an FDA-approved treatment for smallpox, which gives Chimerix an edge as governments explore stockpiling options for poxvirus diseases.Though Chimerix has not explicitly developed a monkeypox treatment, the parallels between smallpox and monkeypox suggest that Tembexa could play a role in mitigating the effects of the outbreak. The drug's broad-spectrum antiviral activity makes it a candidate for off-label use in monkeypox cases. In a market where few treatments exist, Chimerix’s existing FDA approval for Tembexa may provide a quicker pathway for emergency use if the monkeypox crisis intensifies.<ul><li>1-Day Return: +5%</li><li>1-Month Return: +20%</li><li>1-Year Return: +14%</li></ul>Chimerix’s stock has seen a short-term bump as investors reevaluate its smallpox drug in light of the monkeypox outbreak. However, much like Tonix, the stock’s performance over the past year has been challenging, marked by sell-offs and investor uncertainty around the company’s long-term prospects.ConclusionAs monkeypox continues to spread, the market is once again turning to biopharmaceutical companies for solutions.&nbsp;GeoVax Labs,&nbsp;Tonix Pharmaceuticals, and&nbsp;Chimerix Inc. are at the forefront of efforts to address this public health crisis, each leveraging its expertise in smallpox and viral disease research. While the global market for monkeypox treatments is still emerging, these companies are well-positioned to capture the growing demand for vaccines and antiviral treatments.Investors should keep a close eye on clinical developments, regulatory approvals, and government stockpiling programs, as these will be key drivers of stock performance in the coming months. Like the COVID-19 pandemic, the monkeypox outbreak has the potential to create significant winners in the biotech sector. However, as always with biopharma stocks, the risks are high, and careful due diligence is necessary before jumping into this volatile space.&nbsp;Read Next:&nbsp;<a href="https://wealthyvc.com/featured/tiny-healthcare-stock-with-35-million-market-cap-becomes-major-player-overnight-in-rapidly-growing-1-billion-market/">This Tiny Healthcare Stock With $35M Market Cap Becomes Major Player Overnight in Rapidly Growing $1 Billion Blood Clot Market</a><a href="https://www.facebook.com/groups/WealthyVC">Join the Discussion in the WVC Facebook Investor Group</a>Have a Stock Tip or New&nbsp; Story Suggestion? Email us at&nbsp;<a href="mailto:Invest@WealthyVC.com">Invest@WealthyVC.com</a>This article is from an unpaid external contributor. It does not represent Stocktwits reporting or views and has not been edited for content or accuracy.&nbsp;&nbsp;

These Three Stocks are Experiencing an Outbreak– Or a Breakout Depending How you Look at it

GeoVax Labs, Tonix Pharmaceuticals, and Chimerix see stock surge amid monkeypox outbreak, leveraging their expertise in viral diseases and smallpox-related vaccines.

Monkeypox Outbreak Boosts These Biopharma Stocks

The monkeypox outbreak has boosted stocks of GeoVax Labs, Tonix Pharmaceuticals, and Chimerix. These companies are developing vaccines and treatments related to smallpox and viral diseases, positioning them as key players in addressing this health crisis.

Chimerix Board Changes: Machado Resigns, Kozin Appointed

The latest announcement is out from Chimerix (CMRX). Patrick Machado has announced his resignation from the Board of Directors of Chimerix, Inc., e...

Chimerix Appoints Marc D. Kozin to Board of Directors

Veteran Industry Executive Brings More Than 35 Years of Corporate Strategy ExperienceDURHAM, N.C., March 21, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose...

Chimerix (NASDAQ:CMRX) Raised to "Hold" at StockNews.com

StockNews.com upgraded shares of Chimerix (NASDAQ:CMRX  Free Report) from a sell rating to a hold rating in a research report released on Monday.
Other research analysts also recently issued...

Chimerix Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag

Chimerix ( NASDAQ:CMRX ) Full Year 2023 Results Key Financial Results Net loss: US$82.1m (down by 148% from US$172.2m...

Chimerix: Tackling A Strong Unmet Need With Promising Data

Chimerix: Tackling A Strong Unmet Need With Promising Data...

Chimerix files $250M mixed securities shelf

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Chimerix Reports Fourth Quarter and Year End 2023 Financial Results and Provides Operational Update

ONC201 ACTION Study Progressing; Reiterate Interim OS Data Expected in 2025, Final OS Data Expected in 2026 Phase 2 ONC201 Data Published in Peer-Reviewed Journal of Clinical Oncology $204...

Chimerix, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes Brincidofovir for the treatment of adenovirus, cytomegalovirus, and smallpox. The company was founded in April 2000 and is headquartered in Durham, NC.

Chimerix Inc

Bullish: S&P grinds higher

Choppy but up: buy dips

Sideways: fade the move

Bearish: this rally falls off

The Federal Reserve just announced a 0.25 percentage point interest rate cut at its December 10, 2025 meeting.​ Share your outlook on how the latest Federal Reserve interest rate cut will impact stocks and the S&P 500 over the next month.

How do you think today’s Fed rate cut impacts stocks over the next month?

CMRX
Chimerix Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest CMRX News

CMRXChimerix Inc